Biohaven Shares Outstanding 2016-2022 | BHVN

Biohaven shares outstanding from 2016 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Biohaven Annual Shares Outstanding
(Millions of Shares)
2021 65
2020 59
2019 48
2018 39
2017 28
2016 13
2015 11
Biohaven Quarterly Shares Outstanding
(Millions of Shares)
2022-09-30 39
2022-06-30 71
2022-03-31 70
2021-12-31 65
2021-09-30 39
2021-06-30 65
2021-03-31 62
2020-12-31 59
2020-09-30 60
2020-06-30 59
2020-03-31 56
2019-12-31 48
2019-09-30 52
2019-06-30 45
2019-03-31 44
2018-12-31 39
2018-09-30 40
2018-06-30 39
2018-03-31 37
2017-12-31 28
2017-09-30 36
2017-06-30 26
2017-03-31 13
2016-12-31 13
2016-09-30 13
2016-06-30 13
2016-03-31 12
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.266B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00